CL2022002641A1 - Agente para el tratamiento de lesión renal aguda inducida por medio de contraste - Google Patents

Agente para el tratamiento de lesión renal aguda inducida por medio de contraste

Info

Publication number
CL2022002641A1
CL2022002641A1 CL2022002641A CL2022002641A CL2022002641A1 CL 2022002641 A1 CL2022002641 A1 CL 2022002641A1 CL 2022002641 A CL2022002641 A CL 2022002641A CL 2022002641 A CL2022002641 A CL 2022002641A CL 2022002641 A1 CL2022002641 A1 CL 2022002641A1
Authority
CL
Chile
Prior art keywords
contrast
kidney injury
agent
treatment
acute kidney
Prior art date
Application number
CL2022002641A
Other languages
English (en)
Inventor
Jin Lee Soo
Hwan Moon Sung
Original Assignee
Aptabio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210036838A external-priority patent/KR102308991B1/ko
Application filed by Aptabio Therapeutics Inc filed Critical Aptabio Therapeutics Inc
Publication of CL2022002641A1 publication Critical patent/CL2022002641A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención provee una composición farmacéutica para proteger el riñón al reducir la nefrotoxicidad inducida por medio de contraste o para tratar la lesión renal aguda inducida por medio de contraste, que comprende un compuesto de la Fórmula 1, que es un derivado de pirazol, o una sal farmacéuticamente aceptable del mismo.
CL2022002641A 2020-04-08 2022-09-27 Agente para el tratamiento de lesión renal aguda inducida por medio de contraste CL2022002641A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200042899 2020-04-08
KR1020210036838A KR102308991B1 (ko) 2020-04-08 2021-03-22 조영제 유발 급성 신부전 치료제

Publications (1)

Publication Number Publication Date
CL2022002641A1 true CL2022002641A1 (es) 2023-06-16

Family

ID=78023776

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002641A CL2022002641A1 (es) 2020-04-08 2022-09-27 Agente para el tratamiento de lesión renal aguda inducida por medio de contraste

Country Status (11)

Country Link
US (1) US20230201179A1 (es)
EP (1) EP4134079A4 (es)
JP (2) JP7553595B2 (es)
CN (1) CN115413239A (es)
AU (1) AU2021253243B2 (es)
BR (1) BR112022020283A2 (es)
CA (1) CA3172610A1 (es)
CL (1) CL2022002641A1 (es)
CO (1) CO2022014272A2 (es)
MX (1) MX2022012472A (es)
WO (1) WO2021206316A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114288427A (zh) * 2022-03-01 2022-04-08 福建宸润生物科技有限公司 一种肠胃道口服ct造影剂
CN115990166B (zh) * 2023-02-20 2023-09-15 牡丹江医学院 一种预防ct造影剂肾病的药物组合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
CN101166735A (zh) * 2005-04-26 2008-04-23 神经研究公司 新颖的二唑衍生物及其医药应用
JP2010513219A (ja) 2006-12-22 2010-04-30 ベラス ヘルス （インターナショナル） リミテッド 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療
ES2499017T3 (es) * 2007-10-23 2014-09-26 F. Hoffmann-La Roche Ag Nuevos inhibidores de quinasa
WO2009108695A2 (en) 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
WO2011028043A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
KR101633957B1 (ko) * 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
RU2015117483A (ru) * 2012-10-12 2016-12-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинации
SG11201510678TA (en) * 2013-06-28 2016-01-28 Abbvie Inc Bromodomain inhibitors
CN106535921A (zh) 2014-04-15 2017-03-22 安特卫普大学 肾病的治疗
KR20170086851A (ko) * 2016-01-19 2017-07-27 임대식 신장보호용 약학조성물과 신장보호활성을 갖는 조영제 조성물
KR101856444B1 (ko) * 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
EP3650484A4 (en) 2017-07-06 2021-03-24 Kyoto Pharmaceutical University ACTIVE SUBSTANCE RELEASE CARRIERS DIRECTED TO THE KIDNEYS
US11245115B2 (en) 2017-08-29 2022-02-08 Zeon Corporation Binder composition for non-aqueous secondary battery electrode, slurry composition for non-aqueous secondary battery electrode, electrode for non-aqueous secondary battery, and non-aqueous secondary battery
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR20210036838A (ko) 2019-09-26 2021-04-05 솔브레인 주식회사 무기산화물 입자로 표면개질된 세륨옥사이드 플레이크 및 이를 포함하는 자외선 차단제 조성물

Also Published As

Publication number Publication date
JP2023520920A (ja) 2023-05-22
CO2022014272A2 (es) 2022-10-21
CN115413239A (zh) 2022-11-29
AU2021253243A1 (en) 2022-10-13
EP4134079A4 (en) 2024-04-24
AU2021253243B2 (en) 2024-01-18
JP2024138095A (ja) 2024-10-07
US20230201179A1 (en) 2023-06-29
CA3172610A1 (en) 2021-10-14
BR112022020283A2 (pt) 2022-12-06
MX2022012472A (es) 2022-12-15
EP4134079A1 (en) 2023-02-15
JP7553595B2 (ja) 2024-09-18
WO2021206316A1 (ko) 2021-10-14

Similar Documents

Publication Publication Date Title
CL2022002641A1 (es) Agente para el tratamiento de lesión renal aguda inducida por medio de contraste
BR112022025037A2 (pt) Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
CL2020000860A1 (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
GT200600160A (es) Tratamiento del dolor
ECSP23020167A (es) Inhibidores de apol1 y métodos para usar los mismos
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
UY39150A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
DOP2021000254A (es) Compuestos de pirrolidina
UY39799A (es) Compuestos de pirrolil–sulfonamida
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
AR057403A1 (es) 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal
AR126552A1 (es) Composición farmacéutica para prevenir o tratar la esclerosis sistémica
CO2022014273A2 (es) Medicamentos para fibrosis pulmonar que contienen derivado de pirazol
CL2023000731A1 (es) Compuestos para tratar infecciones por virus.
CO2024009030A2 (es) Composición farmacéutica para prevenir o tratar cáncer de mama triple negativo
CO2024002712A2 (es) Azálidos inmunomoduladores
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis